BeyondSpring (NASDAQ:BYSI – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.49, Zacks reports.
BeyondSpring Price Performance
NASDAQ BYSI traded up $0.00 during mid-day trading on Friday, hitting $0.60. The company’s stock had a trading volume of 33,174 shares, compared to its average volume of 143,847. The firm has a market capitalization of $24.72 million, a P/E ratio of -5.01 and a beta of -0.12. BeyondSpring has a 52-week low of $0.42 and a 52-week high of $2.44. The stock’s fifty day simple moving average is $0.66 and its two-hundred day simple moving average is $1.22.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has a consensus rating of “Sell”.
About BeyondSpring
BeyondSpring is a biopharmaceutical company focused on developing therapies for cancer and complications associated with cancer treatment. Its research and development activities center on oncology drug candidates and supportive-care treatments. The company’s lead candidate is plinabulin, a small-molecule drug being investigated for use in preventing chemotherapy-induced neutropenia, a potentially serious drop in infection-fighting white blood cells. BeyondSpring has also studied plinabulin for its potential anti-cancer effects, including in lung cancer.
Read More
- Five stocks we like better than BeyondSpring
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
